Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)Thomas Bachelot, A Wroński, Eva Ciruelos et al.|Annals of Oncology|2019Cited by 117
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognosticationDavid Miles, Hamdy Abdel Azeem, Eva Ciruelos et al.|Annals of Oncology|2021Cited by 92
Guidelines, “minimal requirements” and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working partyYazid Belkacémi, F. Terkmani, F. Dhermain et al.|Critical Reviews in Oncology/Hematology|2015Cited by 5